Table of Content

1 Multiple Sclerosis (MS) Drugs Market Overview
1.1 Product Overview and Scope of Multiple Sclerosis (MS) Drugs
1.2 Multiple Sclerosis (MS) Drugs Segment by Type
1.2.1 Global Multiple Sclerosis (MS) Drugs Market Value Comparison by Type (2024-2034)
1.2.2 Copaxone (Glatiramer Acetate, Copolymer 1)
1.2.3 Novantrone (Mitoxantrone)
1.2.4 Gilenya (Fingolimod, Fty720)
1.2.5 Aubagio (Teriflunomide)
1.2.6 Tecfidera (Dimethyl Fumarate)
1.2.7 Firategrast (Sb683699, T-0047)
1.2.8 Siponimod (Baf312)
1.2.9 Others
1.3 Multiple Sclerosis (MS) Drugs Segment by Application
1.3.1 Global Multiple Sclerosis (MS) Drugs Market Value by Application: (2024-2034)
1.3.2 RRMS
1.3.3 SPMS
1.3.4 PPMS
1.3.5 PRMS
1.4 Global Multiple Sclerosis (MS) Drugs Market Size Estimates and Forecasts
1.4.1 Global Multiple Sclerosis (MS) Drugs Revenue 2018-2034
1.4.2 Global Multiple Sclerosis (MS) Drugs Sales 2018-2034
1.4.3 Global Multiple Sclerosis (MS) Drugs Market Average Price (2018-2034)
1.5 Assumptions and Limitations
2 Multiple Sclerosis (MS) Drugs Market Competition by Manufacturers
2.1 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Manufacturers (2018-2024)
2.2 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Multiple Sclerosis (MS) Drugs Average Price by Manufacturers (2018-2024)
2.4 Global Multiple Sclerosis (MS) Drugs Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Multiple Sclerosis (MS) Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Multiple Sclerosis (MS) Drugs, Product Type & Application
2.7 Multiple Sclerosis (MS) Drugs Market Competitive Situation and Trends
2.7.1 Multiple Sclerosis (MS) Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Multiple Sclerosis (MS) Drugs Players Market Share by Revenue
2.7.3 Global Multiple Sclerosis (MS) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Multiple Sclerosis (MS) Drugs Retrospective Market Scenario by Region
3.1 Global Multiple Sclerosis (MS) Drugs Market Size by Region: 2018 Versus 2022 Versus 2034
3.2 Global Multiple Sclerosis (MS) Drugs Global Multiple Sclerosis (MS) Drugs Sales by Region: 2018-2034
3.2.1 Global Multiple Sclerosis (MS) Drugs Sales by Region: 2018-2024
3.2.2 Global Multiple Sclerosis (MS) Drugs Sales by Region: 2024-2034
3.3 Global Multiple Sclerosis (MS) Drugs Global Multiple Sclerosis (MS) Drugs Revenue by Region: 2018-2034
3.3.1 Global Multiple Sclerosis (MS) Drugs Revenue by Region: 2018-2024
3.3.2 Global Multiple Sclerosis (MS) Drugs Revenue by Region: 2024-2034
3.4 North America Multiple Sclerosis (MS) Drugs Market Facts & Figures by Country
3.4.1 North America Multiple Sclerosis (MS) Drugs Market Size by Country: 2018 VS 2022 VS 2034
3.4.2 North America Multiple Sclerosis (MS) Drugs Sales by Country (2018-2034)
3.4.3 North America Multiple Sclerosis (MS) Drugs Revenue by Country (2018-2034)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Multiple Sclerosis (MS) Drugs Market Facts & Figures by Country
3.5.1 Europe Multiple Sclerosis (MS) Drugs Market Size by Country: 2018 VS 2022 VS 2034
3.5.2 Europe Multiple Sclerosis (MS) Drugs Sales by Country (2018-2034)
3.5.3 Europe Multiple Sclerosis (MS) Drugs Revenue by Country (2018-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Multiple Sclerosis (MS) Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Multiple Sclerosis (MS) Drugs Market Size by Country: 2018 VS 2022 VS 2034
3.6.2 Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Country (2018-2034)
3.6.3 Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Country (2018-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Multiple Sclerosis (MS) Drugs Market Facts & Figures by Country
3.7.1 Latin America Multiple Sclerosis (MS) Drugs Market Size by Country: 2018 VS 2022 VS 2034
3.7.2 Latin America Multiple Sclerosis (MS) Drugs Sales by Country (2018-2034)
3.7.3 Latin America Multiple Sclerosis (MS) Drugs Revenue by Country (2018-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Size by Country: 2018 VS 2022 VS 2034
3.8.2 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Country (2018-2034)
3.8.3 Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue by Country (2018-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Multiple Sclerosis (MS) Drugs Sales by Type (2018-2034)
4.1.1 Global Multiple Sclerosis (MS) Drugs Sales by Type (2018-2024)
4.1.2 Global Multiple Sclerosis (MS) Drugs Sales by Type (2024-2034)
4.1.3 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2018-2034)
4.2 Global Multiple Sclerosis (MS) Drugs Revenue by Type (2018-2034)
4.2.1 Global Multiple Sclerosis (MS) Drugs Revenue by Type (2018-2024)
4.2.2 Global Multiple Sclerosis (MS) Drugs Revenue by Type (2024-2034)
4.2.3 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2018-2034)
4.3 Global Multiple Sclerosis (MS) Drugs Price by Type (2018-2034)
5 Segment by Application
5.1 Global Multiple Sclerosis (MS) Drugs Sales by Application (2018-2034)
5.1.1 Global Multiple Sclerosis (MS) Drugs Sales by Application (2018-2024)
5.1.2 Global Multiple Sclerosis (MS) Drugs Sales by Application (2024-2034)
5.1.3 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2018-2034)
5.2 Global Multiple Sclerosis (MS) Drugs Revenue by Application (2018-2034)
5.2.1 Global Multiple Sclerosis (MS) Drugs Revenue by Application (2018-2024)
5.2.2 Global Multiple Sclerosis (MS) Drugs Revenue by Application (2024-2034)
5.2.3 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2018-2034)
5.3 Global Multiple Sclerosis (MS) Drugs Price by Application (2018-2034)
6 Key Companies Profiled
6.1 Bayer AG
6.1.1 Bayer AG Corporation Information
6.1.2 Bayer AG Description and Business Overview
6.1.3 Bayer AG Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
6.1.4 Bayer AG Multiple Sclerosis (MS) Drugs Product Portfolio
6.1.5 Bayer AG Recent Developments/Updates
6.2 Bayhill Therapeutics
6.2.1 Bayhill Therapeutics Corporation Information
6.2.2 Bayhill Therapeutics Description and Business Overview
6.2.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
6.2.4 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
6.2.5 Bayhill Therapeutics Recent Developments/Updates
6.3 Biogen Idec
6.3.1 Biogen Idec Corporation Information
6.3.2 Biogen Idec Description and Business Overview
6.3.3 Biogen Idec Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Biogen Idec Multiple Sclerosis (MS) Drugs Product Portfolio
6.3.5 Biogen Idec Recent Developments/Updates
6.4 Cinnagen
6.4.1 Cinnagen Corporation Information
6.4.2 Cinnagen Description and Business Overview
6.4.3 Cinnagen Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Cinnagen Multiple Sclerosis (MS) Drugs Product Portfolio
6.4.5 Cinnagen Recent Developments/Updates
6.5 Daiichi Sankyo
6.5.1 Daiichi Sankyo Corporation Information
6.5.2 Daiichi Sankyo Description and Business Overview
6.5.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
6.5.4 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Portfolio
6.5.5 Daiichi Sankyo Recent Developments/Updates
6.6 Eli Lilly
6.6.1 Eli Lilly Corporation Information
6.6.2 Eli Lilly Description and Business Overview
6.6.3 Eli Lilly Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
6.6.4 Eli Lilly Multiple Sclerosis (MS) Drugs Product Portfolio
6.6.5 Eli Lilly Recent Developments/Updates
6.7 Fast Forward Llc
6.6.1 Fast Forward Llc Corporation Information
6.6.2 Fast Forward Llc Description and Business Overview
6.6.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Portfolio
6.7.5 Fast Forward Llc Recent Developments/Updates
6.8 Antisense Therapeutics
6.8.1 Antisense Therapeutics Corporation Information
6.8.2 Antisense Therapeutics Description and Business Overview
6.8.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
6.8.4 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
6.8.5 Antisense Therapeutics Recent Developments/Updates
6.9 Apitope
6.9.1 Apitope Corporation Information
6.9.2 Apitope Description and Business Overview
6.9.3 Apitope Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
6.9.4 Apitope Multiple Sclerosis (MS) Drugs Product Portfolio
6.9.5 Apitope Recent Developments/Updates
6.10 Five Prime Therapeutics
6.10.1 Five Prime Therapeutics Corporation Information
6.10.2 Five Prime Therapeutics Description and Business Overview
6.10.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
6.10.4 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
6.10.5 Five Prime Therapeutics Recent Developments/Updates
6.11 Genmab
6.11.1 Genmab Corporation Information
6.11.2 Genmab Multiple Sclerosis (MS) Drugs Description and Business Overview
6.11.3 Genmab Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
6.11.4 Genmab Multiple Sclerosis (MS) Drugs Product Portfolio
6.11.5 Genmab Recent Developments/Updates
6.12 Artielle Immunotherapeutics
6.12.1 Artielle Immunotherapeutics Corporation Information
6.12.2 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Description and Business Overview
6.12.3 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
6.12.4 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
6.12.5 Artielle Immunotherapeutics Recent Developments/Updates
6.13 Genzyme
6.13.1 Genzyme Corporation Information
6.13.2 Genzyme Multiple Sclerosis (MS) Drugs Description and Business Overview
6.13.3 Genzyme Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
6.13.4 Genzyme Multiple Sclerosis (MS) Drugs Product Portfolio
6.13.5 Genzyme Recent Developments/Updates
6.14 Glaxosmithkline
6.14.1 Glaxosmithkline Corporation Information
6.14.2 Glaxosmithkline Multiple Sclerosis (MS) Drugs Description and Business Overview
6.14.3 Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
6.14.4 Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Portfolio
6.14.5 Glaxosmithkline Recent Developments/Updates
6.15 Gw Pharmaceuticals
6.15.1 Gw Pharmaceuticals Corporation Information
6.15.2 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Description and Business Overview
6.15.3 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
6.15.4 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Portfolio
6.15.5 Gw Pharmaceuticals Recent Developments/Updates
6.16 Innate Immunotherapeutics
6.16.1 Innate Immunotherapeutics Corporation Information
6.16.2 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Description and Business Overview
6.16.3 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2018-2024)
6.16.4 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
6.16.5 Innate Immunotherapeutics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Multiple Sclerosis (MS) Drugs Industry Chain Analysis
7.2 Multiple Sclerosis (MS) Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Multiple Sclerosis (MS) Drugs Production Mode & Process
7.4 Multiple Sclerosis (MS) Drugs Sales and Marketing
7.4.1 Multiple Sclerosis (MS) Drugs Sales Channels
7.4.2 Multiple Sclerosis (MS) Drugs Distributors
7.5 Multiple Sclerosis (MS) Drugs Customers
8 Multiple Sclerosis (MS) Drugs Market Dynamics
8.1 Multiple Sclerosis (MS) Drugs Industry Trends
8.2 Multiple Sclerosis (MS) Drugs Market Drivers
8.3 Multiple Sclerosis (MS) Drugs Market Challenges
8.4 Multiple Sclerosis (MS) Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Multiple Sclerosis (MS) Drugs Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Multiple Sclerosis (MS) Drugs Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Multiple Sclerosis (MS) Drugs Market Competitive Situation by Manufacturers in 2022
Table 4. Global Multiple Sclerosis (MS) Drugs Sales (K Pcs) of Key Manufacturers (2018-2024)
Table 5. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Multiple Sclerosis (MS) Drugs Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Multiple Sclerosis (MS) Drugs Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Multiple Sclerosis (MS) Drugs Average Price (USD/Pcs) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Multiple Sclerosis (MS) Drugs, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Multiple Sclerosis (MS) Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Multiple Sclerosis (MS) Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Multiple Sclerosis (MS) Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Multiple Sclerosis (MS) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multiple Sclerosis (MS) Drugs as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Multiple Sclerosis (MS) Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2034
Table 17. Global Multiple Sclerosis (MS) Drugs Sales by Region (2018-2024) & (K Pcs)
Table 18. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Region (2018-2024)
Table 19. Global Multiple Sclerosis (MS) Drugs Sales by Region (2024-2034) & (K Pcs)
Table 20. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Region (2024-2034)
Table 21. Global Multiple Sclerosis (MS) Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Region (2018-2024)
Table 23. Global Multiple Sclerosis (MS) Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Region (2024-2034)
Table 25. North America Multiple Sclerosis (MS) Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 26. North America Multiple Sclerosis (MS) Drugs Sales by Country (2018-2024) & (K Pcs)
Table 27. North America Multiple Sclerosis (MS) Drugs Sales by Country (2024-2034) & (K Pcs)
Table 28. North America Multiple Sclerosis (MS) Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Multiple Sclerosis (MS) Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Multiple Sclerosis (MS) Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 31. Europe Multiple Sclerosis (MS) Drugs Sales by Country (2018-2024) & (K Pcs)
Table 32. Europe Multiple Sclerosis (MS) Drugs Sales by Country (2024-2034) & (K Pcs)
Table 33. Europe Multiple Sclerosis (MS) Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Multiple Sclerosis (MS) Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 36. Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Region (2018-2024) & (K Pcs)
Table 37. Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Region (2024-2034) & (K Pcs)
Table 38. Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Multiple Sclerosis (MS) Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 41. Latin America Multiple Sclerosis (MS) Drugs Sales by Country (2018-2024) & (K Pcs)
Table 42. Latin America Multiple Sclerosis (MS) Drugs Sales by Country (2024-2034) & (K Pcs)
Table 43. Latin America Multiple Sclerosis (MS) Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Multiple Sclerosis (MS) Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 46. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales by Country (2018-2024) & (K Pcs)
Table 47. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales by Country (2024-2034) & (K Pcs)
Table 48. Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Type (2018-2024)
Table 51. Global Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Type (2024-2034)
Table 52. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2018-2024)
Table 53. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2024-2034)
Table 54. Global Multiple Sclerosis (MS) Drugs Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Multiple Sclerosis (MS) Drugs Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2018-2024)
Table 57. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2024-2034)
Table 58. Global Multiple Sclerosis (MS) Drugs Price (USD/Pcs) by Type (2018-2024)
Table 59. Global Multiple Sclerosis (MS) Drugs Price (USD/Pcs) by Type (2024-2034)
Table 60. Global Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Application (2018-2024)
Table 61. Global Multiple Sclerosis (MS) Drugs Sales (K Pcs) by Application (2024-2034)
Table 62. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2018-2024)
Table 63. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2024-2034)
Table 64. Global Multiple Sclerosis (MS) Drugs Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Multiple Sclerosis (MS) Drugs Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2018-2024)
Table 67. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2024-2034)
Table 68. Global Multiple Sclerosis (MS) Drugs Price (USD/Pcs) by Application (2018-2024)
Table 69. Global Multiple Sclerosis (MS) Drugs Price (USD/Pcs) by Application (2024-2034)
Table 70. Bayer AG Corporation Information
Table 71. Bayer AG Description and Business Overview
Table 72. Bayer AG Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 73. Bayer AG Multiple Sclerosis (MS) Drugs Product
Table 74. Bayer AG Recent Developments/Updates
Table 75. Bayhill Therapeutics Corporation Information
Table 76. Bayhill Therapeutics Description and Business Overview
Table 77. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 78. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product
Table 79. Bayhill Therapeutics Recent Developments/Updates
Table 80. Biogen Idec Corporation Information
Table 81. Biogen Idec Description and Business Overview
Table 82. Biogen Idec Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 83. Biogen Idec Multiple Sclerosis (MS) Drugs Product
Table 84. Biogen Idec Recent Developments/Updates
Table 85. Cinnagen Corporation Information
Table 86. Cinnagen Description and Business Overview
Table 87. Cinnagen Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 88. Cinnagen Multiple Sclerosis (MS) Drugs Product
Table 89. Cinnagen Recent Developments/Updates
Table 90. Daiichi Sankyo Corporation Information
Table 91. Daiichi Sankyo Description and Business Overview
Table 92. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 93. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product
Table 94. Daiichi Sankyo Recent Developments/Updates
Table 95. Eli Lilly Corporation Information
Table 96. Eli Lilly Description and Business Overview
Table 97. Eli Lilly Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 98. Eli Lilly Multiple Sclerosis (MS) Drugs Product
Table 99. Eli Lilly Recent Developments/Updates
Table 100. Fast Forward Llc Corporation Information
Table 101. Fast Forward Llc Description and Business Overview
Table 102. Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 103. Fast Forward Llc Multiple Sclerosis (MS) Drugs Product
Table 104. Fast Forward Llc Recent Developments/Updates
Table 105. Antisense Therapeutics Corporation Information
Table 106. Antisense Therapeutics Description and Business Overview
Table 107. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 108. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product
Table 109. Antisense Therapeutics Recent Developments/Updates
Table 110. Apitope Corporation Information
Table 111. Apitope Description and Business Overview
Table 112. Apitope Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 113. Apitope Multiple Sclerosis (MS) Drugs Product
Table 114. Apitope Recent Developments/Updates
Table 115. Five Prime Therapeutics Corporation Information
Table 116. Five Prime Therapeutics Description and Business Overview
Table 117. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 118. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product
Table 119. Five Prime Therapeutics Recent Developments/Updates
Table 120. Genmab Corporation Information
Table 121. Genmab Description and Business Overview
Table 122. Genmab Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 123. Genmab Multiple Sclerosis (MS) Drugs Product
Table 124. Genmab Recent Developments/Updates
Table 125. Artielle Immunotherapeutics Corporation Information
Table 126. Artielle Immunotherapeutics Description and Business Overview
Table 127. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 128. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product
Table 129. Artielle Immunotherapeutics Recent Developments/Updates
Table 130. Genzyme Corporation Information
Table 131. Genzyme Description and Business Overview
Table 132. Genzyme Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 133. Genzyme Multiple Sclerosis (MS) Drugs Product
Table 134. Genzyme Recent Developments/Updates
Table 135. Glaxosmithkline Corporation Information
Table 136. Glaxosmithkline Description and Business Overview
Table 137. Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 138. Glaxosmithkline Multiple Sclerosis (MS) Drugs Product
Table 139. Glaxosmithkline Recent Developments/Updates
Table 140. Gw Pharmaceuticals Corporation Information
Table 141. Gw Pharmaceuticals Description and Business Overview
Table 142. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 143. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product
Table 144. Gw Pharmaceuticals Recent Developments/Updates
Table 145. Innate Immunotherapeutics Corporation Information
Table 146. Innate Immunotherapeutics Description and Business Overview
Table 147. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 148. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product
Table 149. Innate Immunotherapeutics Recent Developments/Updates
Table 150. Key Raw Materials Lists
Table 151. Raw Materials Key Suppliers Lists
Table 152. Multiple Sclerosis (MS) Drugs Distributors List
Table 153. Multiple Sclerosis (MS) Drugs Customers List
Table 154. Multiple Sclerosis (MS) Drugs Market Trends
Table 155. Multiple Sclerosis (MS) Drugs Market Drivers
Table 156. Multiple Sclerosis (MS) Drugs Market Challenges
Table 157. Multiple Sclerosis (MS) Drugs Market Restraints
Table 158. Research Programs/Design for This Report
Table 159. Key Data Information from Secondary Sources
Table 160. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Multiple Sclerosis (MS) Drugs
Figure 2. Global Multiple Sclerosis (MS) Drugs Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Multiple Sclerosis (MS) Drugs Market Share by Type in 2022 & 2034
Figure 4. Copaxone (Glatiramer Acetate, Copolymer 1) Product Picture
Figure 5. Novantrone (Mitoxantrone) Product Picture
Figure 6. Gilenya (Fingolimod, Fty720) Product Picture
Figure 7. Aubagio (Teriflunomide) Product Picture
Figure 8. Tecfidera (Dimethyl Fumarate) Product Picture
Figure 9. Firategrast (Sb683699, T-0047) Product Picture
Figure 10. Siponimod (Baf312) Product Picture
Figure 11. Others Product Picture
Figure 12. Global Multiple Sclerosis (MS) Drugs Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 13. Global Multiple Sclerosis (MS) Drugs Market Share by Application in 2022 & 2034
Figure 14. RRMS
Figure 15. SPMS
Figure 16. PPMS
Figure 17. PRMS
Figure 18. Global Multiple Sclerosis (MS) Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 19. Global Multiple Sclerosis (MS) Drugs Market Size (2018-2034) & (US$ Million)
Figure 20. Global Multiple Sclerosis (MS) Drugs Sales (2018-2034) & (K Pcs)
Figure 21. Global Multiple Sclerosis (MS) Drugs Average Price (USD/Pcs) & (2018-2034)
Figure 22. Multiple Sclerosis (MS) Drugs Report Years Considered
Figure 23. Multiple Sclerosis (MS) Drugs Sales Share by Manufacturers in 2022
Figure 24. Global Multiple Sclerosis (MS) Drugs Revenue Share by Manufacturers in 2022
Figure 25. The Global 5 and 10 Largest Multiple Sclerosis (MS) Drugs Players: Market Share by Revenue in 2022
Figure 26. Multiple Sclerosis (MS) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 27. Global Multiple Sclerosis (MS) Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2034
Figure 28. North America Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2018-2034)
Figure 29. North America Multiple Sclerosis (MS) Drugs Revenue Market Share by Country (2018-2034)
Figure 30. U.S. Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 31. Canada Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 32. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2018-2034)
Figure 33. Europe Multiple Sclerosis (MS) Drugs Revenue Market Share by Country (2018-2034)
Figure 34. Germany Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 35. France Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 36. U.K. Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 37. Italy Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 38. Russia Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 39. Asia Pacific Multiple Sclerosis (MS) Drugs Sales Market Share by Region (2018-2034)
Figure 40. Asia Pacific Multiple Sclerosis (MS) Drugs Revenue Market Share by Region (2018-2034)
Figure 41. China Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 42. Japan Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 43. South Korea Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 44. India Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 45. Australia Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 46. Taiwan Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 47. Indonesia Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 48. Thailand Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 49. Malaysia Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 50. Philippines Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 51. Latin America Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2018-2034)
Figure 52. Latin America Multiple Sclerosis (MS) Drugs Revenue Market Share by Country (2018-2034)
Figure 53. Mexico Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 54. Brazil Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 55. Argentina Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 56. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2018-2034)
Figure 57. Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue Market Share by Country (2018-2034)
Figure 58. Turkey Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 59. Saudi Arabia Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 60. U.A.E Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 61. Global Sales Market Share of Multiple Sclerosis (MS) Drugs by Type (2018-2034)
Figure 62. Global Revenue Market Share of Multiple Sclerosis (MS) Drugs by Type (2018-2034)
Figure 63. Global Multiple Sclerosis (MS) Drugs Price (USD/Pcs) by Type (2018-2034)
Figure 64. Global Sales Market Share of Multiple Sclerosis (MS) Drugs by Application (2018-2034)
Figure 65. Global Revenue Market Share of Multiple Sclerosis (MS) Drugs by Application (2018-2034)
Figure 66. Global Multiple Sclerosis (MS) Drugs Price (USD/Pcs) by Application (2018-2034)
Figure 67. Multiple Sclerosis (MS) Drugs Value Chain
Figure 68. Multiple Sclerosis (MS) Drugs Production Process
Figure 69. Channels of Distribution (Direct Vs Distribution)
Figure 70. Distributors Profiles
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed